Sara Jordan, MD
Gynecologic Oncology · Rio Rancho, NMNPI 1902085822
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Intuitive Surgical at 57.5% of the total. Reporting peaked in 2019 at $2,119 and has fallen 84.3% since, to $333 in 2025.
Across 59 payments — averaging $56.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Genmab U.S., Inc.$366
- Novartis$209
- AstraZeneca$137
- Johnson & Johnson$79
- Tesaro, Inc.$78
- plus $553 from 17 others
What the payments were for
- Travel & lodging$98730%
- Food & beverage$1,56347%
- Education$79324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $1,923 |
| Genmab U.S., Inc. | 4 | $366 |
| Novartis | 11 | $209 |
| AstraZeneca | 4 | $137 |
| Johnson & Johnson | 3 | $79 |
| Tesaro, Inc. | 1 | $78 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Myriad Genetic Laboratories, Inc. | 1 | $65 |
| Exelixis Inc. | 3 | $51 |
| Merck | 2 | $45 |
| Sobi, Inc | 2 | $39 |
| AbbVie | 1 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $34 |
| Genentech USA, Inc. | 1 | $28 |
| Geron Corporation | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Puma Biotechnology, Inc. | 2 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Sanofi | 1 | $18 |
| Gilead | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,620
- TIVDAK$247
How this compares
Too few gynecologic oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 60 | $719,034 |
| LenvimaLenvatinib Mesylate | 13 | $332,973 |
| EliquisApixaban | 15 | $8,891 |
| Prednisolone Acetate | 25 | $1,492 |
| Lactulose | 23 | $523 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 22 | $443 |
| Prochlorperazine Maleate | 29 | $382 |
| Letrozole | 15 | $303 |
| Olanzapine OdtOlanzapine | 17 | $296 |
| Ondansetron Hcl | 18 | $206 |
| Ibuprofen | 19 | $100 |
| Olanzapine | 15 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $137 | $719,03460 claims |
| Eisai Inc.Lenvima | $22 | $332,97313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other gynecologic oncology in Rio Rancho
- Luis Padilla PazAlbuquerque$99K
- Stephanie RiederAlbuquerque$76K
- Ketura WisnerAlbuquerque$23K
- Karen FinkelsteinAlbuquerque$16K
- Amaranta CraigAlbuquerque$8K
- Carolyn MullerAlbuquerque$6K
- Joel WebbAlbuquerque$5K
- Leo TwiggsAlbuquerque$3K
- Sarah AdamsAlbuquerque$521
- Katijane DexterAlbuquerque$510
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.